Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response.

Kodumudi KN, Ramamoorthi G, Snyder C, Basu A, Jia Y, Awshah S, Beyer AP, Wiener D, Lam L, Zhang H, Greene MI, Costa RLB, Czerniecki BJ.

Front Immunol. 2019 Aug 14;10:1939. doi: 10.3389/fimmu.2019.01939. eCollection 2019.

2.

Immunotherapy in breast cancer: Current status and future directions.

Basu A, Ramamoorthi G, Jia Y, Faughn J, Wiener D, Awshah S, Kodumudi K, Czerniecki BJ.

Adv Cancer Res. 2019;143:295-349. doi: 10.1016/bs.acr.2019.03.006. Epub 2019 May 2.

PMID:
31202361
3.

Vaccine Therapies for Breast Cancer.

Burke EE, Kodumudi K, Ramamoorthi G, Czerniecki BJ.

Surg Oncol Clin N Am. 2019 Jul;28(3):353-367. doi: 10.1016/j.soc.2019.02.004. Epub 2019 Apr 5. Review.

PMID:
31079793
4.

Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer.

Poch M, Hall M, Joerger A, Kodumudi K, Beatty M, Innamarato PP, Bunch BL, Fishman MN, Zhang J, Sexton WJ, Pow-Sang JM, Gilbert SM, Spiess PE, Dhillon J, Kelley L, Mullinax J, Sarnaik AA, Pilon-Thomas S.

Oncoimmunology. 2018 Jul 23;7(9):e1476816. doi: 10.1080/2162402X.2018.1476816. eCollection 2018.

5.

Oncodriver inhibition and CD4+ Th1 cytokines cooperate through Stat1 activation to induce tumor senescence and apoptosis in HER2+ and triple negative breast cancer: implications for combining immune and targeted therapies.

Rosemblit C, Datta J, Lowenfeld L, Xu S, Basu A, Kodumudi K, Wiener D, Czerniecki BJ.

Oncotarget. 2018 May 1;9(33):23058-23077. doi: 10.18632/oncotarget.25208. eCollection 2018 May 1.

6.

T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model.

Liu H, Weber A, Morse J, Kodumudi K, Scott E, Mullinax J, Sarnaik AA, Pilon-Thomas S.

PLoS One. 2018 Apr 25;13(4):e0196033. doi: 10.1371/journal.pone.0196033. eCollection 2018.

7.

Intralesional rose bengal in melanoma elicits tumor immunity via activation of dendritic cells by the release of high mobility group box 1.

Liu H, Innamarato PP, Kodumudi K, Weber A, Nemoto S, Robinson JL, Crago G, McCardle T, Royster E, Sarnaik AA, Pilon-Thomas S.

Oncotarget. 2016 Jun 21;7(25):37893-37905. doi: 10.18632/oncotarget.9247.

8.

Immune Checkpoint Blockade to Improve Tumor Infiltrating Lymphocytes for Adoptive Cell Therapy.

Kodumudi KN, Siegel J, Weber AM, Scott E, Sarnaik AA, Pilon-Thomas S.

PLoS One. 2016 Apr 6;11(4):e0153053. doi: 10.1371/journal.pone.0153053. eCollection 2016.

9.

Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy.

Pilon-Thomas S, Kodumudi KN, El-Kenawi AE, Russell S, Weber AM, Luddy K, Damaghi M, Wojtkowiak JW, Mulé JJ, Ibrahim-Hashim A, Gillies RJ.

Cancer Res. 2016 Mar 15;76(6):1381-90. doi: 10.1158/0008-5472.CAN-15-1743. Epub 2015 Dec 30. Erratum in: Cancer Res. 2017 May 1;77(9):2552.

10.

Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer.

Toomey P, Kodumudi K, Weber A, Kuhn L, Moore E, Sarnaik AA, Pilon-Thomas S.

PLoS One. 2013 Jul 17;8(7):e68561. doi: 10.1371/journal.pone.0068561. Print 2013.

11.

Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma.

Ghansah T, Vohra N, Kinney K, Weber A, Kodumudi K, Springett G, Sarnaik AA, Pilon-Thomas S.

Cancer Immunol Immunother. 2013 Jun;62(6):1083-91. doi: 10.1007/s00262-013-1407-9. Epub 2013 Apr 19.

12.

Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma.

Kodumudi KN, Weber A, Sarnaik AA, Pilon-Thomas S.

J Immunol. 2012 Dec 1;189(11):5147-54. doi: 10.4049/jimmunol.1200274. Epub 2012 Oct 24.

13.

Differential expression of TLR-2 and TLR-4 in the epithelial cells in oral lichen planus.

Janardhanam SB, Prakasam S, Swaminathan VT, Kodumudi KN, Zunt SL, Srinivasan M.

Arch Oral Biol. 2012 May;57(5):495-502. doi: 10.1016/j.archoralbio.2011.10.013. Epub 2011 Nov 26.

PMID:
22119043
14.

Icariin and its derivative, ICT, exert anti-inflammatory, anti-tumor effects, and modulate myeloid derived suppressive cells (MDSCs) functions.

Zhou J, Wu J, Chen X, Fortenbery N, Eksioglu E, Kodumudi KN, Pk EB, Dong J, Djeu JY, Wei S.

Int Immunopharmacol. 2011 Jul;11(7):890-8. doi: 10.1016/j.intimp.2011.01.007. Epub 2011 Jan 15.

15.

A combination of two Brugia malayi filarial vaccine candidate antigens (BmALT-2 and BmVAH) enhances immune responses and protection in jirds.

Anand SB, Kodumudi KN, Reddy MV, Kaliraj P.

J Helminthol. 2011 Dec;85(4):442-52. doi: 10.1017/S0022149X10000799. Epub 2011 Jan 4.

PMID:
21208482
16.

A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers.

Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY.

Clin Cancer Res. 2010 Sep 15;16(18):4583-94. doi: 10.1158/1078-0432.CCR-10-0733. Epub 2010 Aug 11.

17.

CD80 blockade enhance glucocorticoid-induced leucine zipper expression and suppress experimental autoimmune encephalomyelitis.

Dudhgaonkar SP, Janardhanam SB, Kodumudi KN, Srinivasan M.

J Immunol. 2009 Dec 1;183(11):7505-13. doi: 10.4049/jimmunol.0902056. Epub 2009 Nov 16.

18.

Suppression of colon inflammation by CD80 blockade: evaluation in two murine models of inflammatory bowel disease.

Eri R, Kodumudi KN, Summerlin DJ, Srinivasan M.

Inflamm Bowel Dis. 2008 Apr;14(4):458-70. doi: 10.1002/ibd.20344.

PMID:
18186109
19.

Soluble CD14 and toll-like receptor-2 are potential salivary biomarkers for oral lichen planus and burning mouth syndrome.

Srinivasan M, Kodumudi KN, Zunt SL.

Clin Immunol. 2008 Jan;126(1):31-7. Epub 2007 Oct 3.

PMID:
17916440

Supplemental Content

Loading ...
Support Center